Selecting Therapy for Steroid-Refractory Chronic GVHD
Dr Gooptu highlights how she selects therapy for a patient who is refractory to steroids for chronic GVHD and Dr Inyang notes the adverse events seen with these therapies.
The Steroid-Refractory Chronic GVHD Landscape
GVHD experts outline the treatment options for patients with steroid-refractory chronic GVHD.
Steroid Administration for Chronic GVHD
Details of steroid use for chronic GVHD, including taper and response criteria, are described by the panel.
Frontline Treatment of Chronic GVHD
The panel provides an overview of the frontline treatments available for chronic GVHD.
Challenges with Early Diagnosis of GVHD
Mahasweta Gooptu, MD shares insights on the early identification and diagnosis of chronic GVHD.
Chronic GVHD Incidence and Risk Factors
Dr Gooptu discusses the incidence of chronic GVHD and ruminates on how a patient’s medical history may impact their chronic GVHD risk.
Clinical Scenario: Chronic Graft Versus Host Disease
Signs and symptoms of chronic GVHD are explained through the lens of the clinical scenario.
Education and Resources for Patients with GVHD
The panel highlights the importance of a multidisciplinary approach and best practices in education for patients with GVHD.
Frontline Steroid Treatment for Acute GVHD
Drs Gootpu and Inyang explain use of corticosteroids as frontline treatment for acute GHVD.
Assessment and Grading of Acute GVHD
Dr Gooptu shares guidance on the assessment and grading of acute GVHD.
Acute GVHD Presentation and Diagnosis
Acute GVHD presentation and diagnosis is assessed for the clinical scenario previously discussed.
The GVHD Prophylaxis Landscape
GVHD prophylaxis techniques are analyzed by the panelists.
Risk Factors for Acute and Chronic GVHD
Dr. Gooptu explains the risk factors associated with both acute and chronic GVHD.
Conditioning Regimens for Stem Cell Transplantation
Eno-Abasi Inyang, PharmD, BCPS, BCOP provides an overview of the various conditioning regimens employed for allogeneic stem cell transplantation.
GVHD Incidence and Pathophysiology
Mahasweta Gooptu, MD, reviews statistics on graft versus host disease and explains the desired graft versus leukemia effect.
Clinical Scenario: A 38-Year-Old Man with Ph+ ALL
Bonnie Dirr, APRN, introduces a clinical scenario of a patient who received an allogeneic stem cell transplant from a sibling donor to begin the panel’s discussion of graft versus host disease.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512